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INTRODUCTION
Posterior reversible encephalopathy syn-
drome (PRES), also named posterior reversible 
leucoencephalopathy syndrome,1 is an increasingly 
recognised clinical and radiological entity, first 
described in 1996 by Hinchey et al.2
Several medical conditions have been associ-
ated with this syndrome, such as systemic arterial 
hypertension (SAH), pre-eclampsia or eclampsia, 
renal dysfunction, several chemotherapeutic and 
immunosuppressant agents, systemic lupus erythe-
matosus or solid organ transplantation,1,3–11 among 
others (Table 1).
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ABSTRACT
Posterior reversible encephalopathy syndrome is an increasingly recognised clinico-radiological 
entity, associated with several medical conditions (such as systemic arterial hypertension) and char-
acterised by seizures, altered mental status, headaches, and visual symptoms. Magnetic resonance 
imaging is a key component in this diagnosis, with hyperintense foci in T2-weighted images, corre-
sponding to vasogenic oedema. The pathophysiology is not fully understood but probably involves 
loss of auto-regulation of cerebral vasculature or endothelial dysfunction or both. A 56-year-old 
male, suffering from a gastro-intestinal stromal tumour with hepatic metastasis resistant to ima-
tinib, on therapy with sunitinib, came to the Emergency Department because of headaches, hallu-
cinations, and loss of vision. There was no previous history of high blood pressure. A hypertensive 
crisis was diagnosed; ophthalmological examination on admission showed no light perception 
bilaterally. Brain imaging displayed bilateral parieto-occipital and frontal vasogenic oedema, con-
sistent with the clinical diagnosis of posterior reversible encephalopathy syndrome. After treatment 
of hypertension and suspension of sunitinib, the patient recovered from his symptoms. Control 
imaging showed no oedema. Angiogenesis inhibitors, such as sunitinib and bevacizumab, can 
cause hypertension, one of the many medical conditions associated with the posterior reversible 
encephalopathy syndrome. This syndrome should be considered in cases of acute visual loss, par-
ticularly in view of its reversible nature when diagnosed and treated promptly.
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The pathophysiology of this entity is not yet fully 
understood. The presence of vasogenic oedema is 
universal,1,3–8 but its origin remains controversial. The 
reversibility of the clinical and radiological changes 
seems to minimize  the importance of cytotoxic 
oedema in this syndrome, although there have been 
cases where both kinds of oedema coexist.6,12
The most widely accepted theory is that severe SAH 
leads to loss of auto-regulation of the cerebral vascula-
ture, with consequent hyperperfusion, endothelial cell 
injury, blood-brain barrier disruption, and formation 
of vasogenic oedema.13
Besides SAH, other contributing mechanisms have 
been put forward, such as endothelial dysfunction sec-
ondary to toxicity,2,6,13 as in cases of cytotoxic therapies, 
or a state of endothelial activation,3,13 as in eclampsia, 
sepsis, or tumour cell lysis after chemotherapy.
Whatever the implicated mechanisms, they all 
seem to be related to a dysfunction at the blood-brain 
barrier level.7 The posterior cerebral circulation is the 
most frequently affected,4,12 due to its relative lack of 
perivascular sympathetic innervation, rendering it 
more susceptible, as there is a more rapid loss of pro-
tective vasoconstriction.4,12,14,15
The clinical picture is characterised by acute or sub-
acute onset of headaches, altered mental status (includ-
ing confusion, lethargy, somnolence, or even coma), 
seizures or visual symptoms,3,12,15 namely blurred vision, 
scotoma,7 hemianopia,5 visual hallucinations,7 visual 
neglect,5 or blindness.6,7 Other features, such as nausea, 
vomiting,10 paresis,12 or other focal deficits may also be 
present.
Ophthalmic examination is almost always nor-
mal, although there may be signs of acute or chronic 
SAH, such as optic disc oedema, haemorrhages, or 
exudates.6,7
Originally described as a subcortical disease of the 
posterior cerebrum,2 with symmetrical changes in both 
parietal and occipital lobes, more recently published 
series have shown different radiological findings and 
patterns, such as cortical involvement, as well as fron-
tal, temporal, or, less commonly, cerebellum, brainstem, 
or basal ganglia lesions.4,6,16 Although it occurs but 
rarely, a unilateral pattern of PRES may be found.7
Brain computed tomographic (CT) imaging may 
be useful as a first examination, exhibiting hypodense 
areas in susceptible regions, but the diagnosis is more 
firmly established using brain magnetic resonance 
imaging (MRI). T2-weighted and fluid-attenuated 
inversion recovery (FLAIR) MRI images show cortical 
and subcortical hyperintensities2–8 corresponding to 
areas of vasogenic oedema. These can be distinguished 
from cytotoxic oedema with the more recent advances 
in MRI technology, such as diffusion-weighted imag-
ing (DWI) and apparent diffusion coefficient (ADC) 
maps (elaborated from the diffusion data).
In DWI, vasogenic oedema has normal or decreased 
signal intensity, differentiating it from cytotoxic 
oedema, with increased signal.8,12 In the same way, 
ADC maps allow distinction between both kinds of 
TABLE 1 Medical conditions associated with PRES3,5,6.
Severe hypertension
Pre-eclampsia/eclampsia
Acute or chronic renal disease
Immunosuppressive drugs
Cyclosporine A
Tacrolimus (FK-506)
High-dose steroids
Interferon alpha
Chemotherapy agents
Cytarabine
Cisplatin
Gemcitabine
Vincristine
Tiazofurin
Bevacizumab
Sunitinib
Sorafenib
Combination chemotherapy (CHOP/CVP)
Other drugs
Intravenous immunoglobulin
Erytropoietin
Granulocyte stimulating factor
Interleukin
Antiretroviral therapy in HIV-infected patients
Infection/sepsis
Autoimmune diseases
Systemic lupus erythematosus
Systemic sclerosis
Wegener´s granulomatosis
Polyarteritis nodosa
Thrombotic thrombocytopenic purpura
Haemolytic uraemic syndrome
Liver failure
Endocrine dysfunctions
Bone marrow transplantation
Solid organ transplantation
Blood transfusion
Tumour lysis syndrome
Hypercalcaemia/hyperparathyroidism
Hypomagnesaemia
Hypocholesterolaemia
Guillain- Barré syndrome
Porphyria
Contrast media exposure
Ephedra overdose
Cocaine or amphetamines abuse
Scorpion envenomation
Hydrogen peroxide
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oedema, with vasogenic oedema showing increased 
signal and decreased signal in cases of cytotoxicity.8,12
Since DWI has signal contributions from both 
underlying T2 weighting as well as diffusion weight-
ing, hyperintensities in this sequence may be due 
to true diffusion restriction (such as infarction) or 
strong T2 effects, the so-called shine-through effect. 
ADC maps are very useful in these particular cases, 
allowing distinction between vasogenic oedema, with 
a bright appearance, and cytotoxic oedema or true 
infarction, with a low signal; this feature may play an 
important role in predicting the final outcome of this 
condition.12
The differential diagnosis of PRES includes a wide 
spectrum of neurological diseases, such as ischaemic 
stroke, infectious encephalitis, cerebral venous throm-
bosis, central nervous system (CNS) vasculitis, or CNS 
neoplasm (especially if unilateral).4,5
Most of the cases are completely reversible with 
control of SAH or removal of the inciting agent. If the 
causative factor is not promptly withdrawn, it may 
lead to ischaemia or haemorrhage and subsequent 
permanent neurological deficits or epilepsy.1,7,15
MATERIALS AND METHODS
We report a single case of PRES following therapy with 
sunitinib.
The patient was assessed by an interdisciplinary 
team of ophthalmologists, neurologists, a neuroradi-
ologist and an oncologist; an extensive investigation 
included brain CT scans and MRI and a Goldmann 
visual field test.
RESULTS
A 56-year-old Caucasian male experienced simple 
visual hallucinations for 3 hours, followed by acute 
bilateral painless loss of vision. On clinical interroga-
tion he complained of mild occipital bilateral head-
aches for the previous 3 weeks.
Past medical history included a gastro-intestinal 
stromal tumour (GIST) diagnosed 12 years before, with 
hepatic metastasis for the last 3 years. The patient had 
undergone multiple surgical interventions and chemo-
therapy cycles, including imatinib for 5 years, to which 
the disease had gained resistance. He was on the 4th 
week of his second cycle of oral therapy with 50 mg/
day of sunitinib (regimen 4 weeks on, 2 weeks off), 
an anti-angiogenic agent. He had completed his first 
treatment 6 weeks before, without any complications. 
He had no other known diseases, specifically no SAH. 
Usual medication, besides chemotherapy, included 
domperidone and omeprazole.
On admission, ophthalmological assessement 
showed no light perception (NLP) in both eyes, pres-
ervation of the pupillary reflexes and normal fundu-
scopic examination, with no other changes. Physical 
examination revealed a blood pressure (BP) elevated at 
210/114 mm Hg, with the rest of the clinical examina-
tion being normal.
Emergent brain CT scan revealed bilateral parieto-
occipital hypodense lesions, possibly related to oedema 
(Figure 1), and the patient was admitted with the pre-
sumptive diagnosis of PRES.
After prompt institution of BP-lowering therapy 
(captopril, furosemide, and amlodipine), BP was nor-
malised by the 3rd day; on that same day he began to 
recover his vision, with a visual acuity of 6/10 OU. 
Concurrently, he started experiencing complex visual 
hallucinations and palinopsia.
On the 4th day, treatment with sunitinib was sus-
pended, thus completing the scheduled course; on the 
same day, a brain MRI was performed, which confirmed 
the diagnosis of PRES. T2 FLAIR images showed cortical 
and subcortical bilateral oedematous lesions in parieto-
occipital regions, as well as in both frontal white and 
grey matter, more evident on the right side (Figures 
2 and 3A). In order to better characterise the oedema, 
DWI was obtained (Figure 3B), showing increased sig-
nal in the parieto-occipital lobes, which was no more 
FIGURE 1 Brain computed tomographic scan, 1st day: parieto-
occipital hypodense lesions, suggestive of oedema (white 
arrows).
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than the shine-through effect, as shown by the ADC 
map, displaying hyperintensities in the posterior lobes 
(Figure 3C). These findings pointed to a vasogenic type 
of oedema, predicting a good outcome.
During hospitalisation, ophthalmological exami-
nation was completely normal, namely the pupillary 
reflexes and the fundus examination.
Visually evoked potentials were normal.
The patient left the hospital on the 8th day, with 
an uncorrected visual acuity of 10/10 but still expe-
riencing visual hallucinations and palinopsia. These 
disappeared progressively over the following 5 weeks. 
BP values were normal on discharge from hospital 
and the patient was left without anti-hypertensive 
medication.
A control brain MRI, performed 6 weeks later, 
showed complete resolution of the lesions (Figure 4). 
Clinical examination (namely ophthalmic and neuro-
logical examinations) and a Goldmann visual field test 
later performed showed no permanent deficits.
DISCUSSION
Sunitinib is a tyrosine-kinase (TK) inhibitor; its anti-
angiogenic activity is mediated by inhibition of the 
vascular endothelial growth factor (VEGF) TK recep-
tor, among other TK receptors.17 It is used mainly in 
renal cell carcinoma and GIST, especially when there 
is metastatic disease.17 Other TK inhibitors in clinical 
use include drugs such as sorafenib, erlotinib, gefitinib, 
lapatinib, nilotinib, and dasatinib.
Bevacizumab, a monoclonal antibody, has also an 
anti-angiogenic activity but through a different mecha-
nism: by binding VEGF, it prevents its interaction with 
its receptors (Flt-1 [VEGFR1] and KDR [kinase insert 
domain receptor; VEGFR2]) on the endothelial cells 
surface, thereby preventing the formation of new blood 
vessels.
Despite being generally well tolerated, angio-
genesis inhibitors may be associated with SAH. The 
exact mechanism by which this occurs is not yet fully 
understood, although vascular rarefaction, endothelial 
dysfunction, or altered nitrous oxide metabolism have 
been suggested.17
We present a case of a patient with no known SAH, 
who was admitted with visual symptoms (visual 
hallucinations and blindness), headaches, and a 
hypertensive crisis. This clinical picture manifested 
on the 4th week of his second treatment cycle with 
sunitinib, after having gained resistance to treatment 
with imatinib.
MRI images showed typical signs of PRES, with 
lesions affecting both cortical and subcortical tissues, 
and involving occipital, parietal, and frontal lobes 
bilaterally; ADC confirmed the vasogenic nature of the 
oedema, the lesions being hyperintense. Repeated neu-
roimaging showed complete resolution of the oedema, 
accounting for the reversibility of this syndrome.
A B
FIGURE 2 Brain MRI, 5th day: FLAIR images showing corti-
cal and subcortical bilateral parieto-occipital (A) and frontal 
lesions (B) (white arrows), corresponding to oedema.
A CB
FLAIR DWI ADC
FIGURE 3 Brain MRI, 5th day. (A-) FLAIR: Hyperintense lesions in the posterior 
lobes, corresponding to oedema (white arrows). (B-) DWI: Discrete hyperintensities 
in the posterior lobes (black arrow heads), corresponding either to shine-trough effect 
or true diffusion restriction. (C-) ADC: Increased hyperintensity in the posterior lobes 
(black arrows), corresponding to vasogenic oedema.
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Although sunitinib was suspended only 4 days 
after his admission, clinical recovery began on the 
3rd day, with improvement in visual acuity (from 
NLP in both eyes to 6/10 OU) following an aggres-
sive  anti-hypertensive therapy. This fact supports the 
theory that SAH, rather than the drug itself and its 
possible direct action on the endothelial cells, was 
the main cause for the loss of vascular auto-regula-
tion of the cerebral circulation, leading to vasogenic 
oedema.
As stated before, several mechanisms may coexist in 
PRES; in this particular case, besides SAH associated 
with a hyperperfusion state and endothelial toxicity 
caused by the drug, one may also speculate whether 
tumour cell lysis could be a contributing factor.
It is questionable whether the patient should have 
stopped treatment with sunitinib as soon as the diag-
nosis of PRES was put forward. After discussion of the 
patient’s condition with the oncologist and since the 
putative trigger of PRES in this case was the abnor-
mally high blood pressure, a decision was made to 
complete the 4-week plan of sunitinib treatment, along 
with treatment of the hypertension.
One question remains unanswered, however: why 
did this occur at this point of treatment, since 6 weeks 
before the patient had completed the same plan with-
out any complications? We can offer no explanation for 
this fact, although it is known that SAH may develop 
either with drug initiation or within the first year of 
treatment with anti-angiogenics.18
Three other cases of PRES associated with sunitinib 
have been described19–21 (Table 2), all of them in the 
context of renal cell carcinomas (which had metas-
tasised to bone, liver and lung, and ovaries, respec-
tively). As with our patient, there was no previous 
history of SAH and all cases had a complete recovery, 
both clinically and radiologically. The clinical picture 
was somewhat different, with partial seizures in one 
patient, confusion in the second one, and headaches 
and generalised seizures in the third case. The delay 
of symptom onset ranged from 1 week to 5 months. 
The presented case is the first report of PRES asso-
ciated with sunitinib presenting with cortical visual 
loss rather than seizures, altered mental status or 
headache.
Reports of PRES associated with bevacizumab22–28 
(Table 2) have been published, all of them with com-
plete or partial resolution.
Sorafenib, another anti-angiogenic drug, has also 
been implicated in cases of PRES29,30 (Table 2).
PRES should be considered in all cases of acute 
cerebral visual loss. Ophthalmologists should be aware 
that they may be the first physicians to examine PRES 
patients and that early diagnosis and treatment may be 
crucial to the reversibility of this process.
In addition, recognizing this syndrome and differen-
tiating it from acute cerebral ischaemia, in the appropri-
ate clinical context (acute hypertension, chemotherapy, 
eclampsia) described above, may prevent institution 
A B
FIGURE 4 MRI, 6th week: FLAIR images showing complete 
resolution of the oedema, both parieto-occipital (A) and 
frontal (B).
TABLE 2  Cases of PRES associated with anti-angiogenics19-–30.
Reference Anti-angiogenic drug Age/sex Underlying disease
Previous history of 
hypertension
Martin et al. (2007)19 Sunitinib 70/F Metastatic renal cell carcinoma No
Medioni et al. (2007)20 Sunitinib 81/F Metastatic renal cell carcinoma No
Cumurcic et al. (2008)21 Sunitinib 39/F Metastatic renal cell carcinoma No
Glusker et al. (2006)22 Bevacizumab 52/F Metastatic renal cancer No
Ozcan et al. (2006)23 Bevacizumab 59/F Metastatic rectal adenocarcinoma No
Jeffrey et al. (2006)24 Bevacizumab 52/M Rectal carcinoma No
Kapiteijn et al. (2007)25 Bevacizumab 54/F Gastrointestinal stromal tumor Yes
Levy et al. (2008)26 Bevacizumab 6/F Hepatoblastoma No
Maalouf et al. (2008)27 Bevacizumab 55/F Metastatic colon cancer No
Koopman et al. (2008)28 Bevacizumab 49/M Colorectal cancer No
Govindarajan et al. (2006)29 Sorafenib 49/F Cholangiocarcinoma No
Dogan et al. (2009)30 Sorafenib 58/M Hepatocellular carcinoma No
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of potentially dangerous invasive procedures, such as 
thrombolytic therapy.
Declaration of interest: The authors report no conflicts 
of interest. The authors alone are responsible for the 
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